Nirsevimab RSV Vaccine Description
Nirsevimab is being developed in partnership with AstraZeneca, which is the first investigational extended half-life monoclonal antibody (mAb) being developed as a passive immunization for the prevention of lower respiratory tract infections (LRTI) caused by RSV. It is designed to protect all infants experiencing their first RSV season and infants with congenital heart disease or chronic lung disease entering their first and second RSV season.
Nirsevimab RSV Vaccine Indication
Nirsevimab is designed to be administered from birth to infants born during the RSV season or at the season’s start for infants entering their first RSV season.
Nirsevimab RSV Vaccine Dosage
Nirsevimab is in clinical trials to determine the proper dosage.
Nirsevimab RSV Vaccine News
June 28, 2021 - Sanofi announced Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
July 30, 2020 - Sanofi published detailed results from the Phase 2b trial for nirsevimab showing a significant reduction in medically attended lower respiratory tract infections (LRTI), mainly bronchiolitis and pneumonia, and hospitalizations caused by the respiratory syncytial virus (RSV) in healthy preterm infants.
Nirsevimab RSV Vaccine Clinical Trials
Nirsevimab has been tested in several clinical trials.